Cite

HARVARD Citation

    Vandenberghe, R. et al. (2016). Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimer's research & therapy. 8 (1), pp. 1-13. [Online]. 
  
Back to record